


1616



# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701

RECEIVED

JUN 21 2001

TECH CENTER 1600/2900

HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG

TELEPHONE: 512/474-5201  
FACSIMILE: 512/536-4598

DAVID L. PARKER  
PARTNER


INTERNET ADDRESS:  
DPARKER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3055

June 15, 2001

FILE: UTXC:528--1

10016657

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
6/15/01 Date	 Signature

Commissioner for Patents  
Washington, DC 20231

RE: SN 09/415,890 "PARENTERAL PIMARICIN AS TREATMENT OF SYSTEMIC INFECTIONS" - Andersson, et al. (MDA96-033CON1)

Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) An Amendment; and Response to Office Action dated March 15, 2001 including Appendices A and B; and
- (2) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.


Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10016657/01982.

Commissioner for Patents

June 15, 2001

Page 2

Respectfully submitted,

 REG. NO. 45,104

FOR

David L. Parker

Reg. No. 32,165

DLP/jmh

Encl.: